Sinonasal malignancy: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up

• Authors: RESTEGHINI C.; BAUJAT B.; BOSSI P.; FRANCHI A.; DE GABORY L.; HALÁMKOVÁ Jana; HAUBNER F.; HARDILLO J. A. U.; HERMSEN M. A.; IACOVELLI N A.; MAROLDI R.; MATTHEIS S.; MOYA-PLANA A.; NICOLAI P.; ORLANDI E.; THARIAT J.; TRAMA A.; VAN DEN BREKEL M. W. M.; VAN HERPEN C. M. L.; VERILLAUD B.; KINLOCH E.; LICITRA L.; EVEN C.
• Year of publication: 2025
• Type: Article in Periodical
• Magazine / Source: ESMO OPEN
• MU Faculty or unit: Faculty of Medicine
• web: https://www.sciencedirect.com/science/article/pii/S2059702924018921?via%3Dihub
• Doi: https://doi.org/10.1016/j.esmoop.2024.104121
• Keywords: endoscopic surgery; (neoadjuvant) chemotherapy; radiotherapy; proton therapy; sinonasal carcinomas
• Description: The term sinonasal malignancies (SMs) groups together many tumours of variable histology and biological behaviour. This Clinical Practice Guideline (CPG) covers the histotypes included in the fifth edition of the World Health Organization classification of tumours of the nasal cavity, paranasal sinuses and skull base (see Supplementary Table S1, available at https://doi.org/10.1016/j.esmoop.2024.104121) under ‘carcinomas’, ‘adenocarcinomas’ and ‘olfactory neuroblastomas’. Additionally, this CPG covers neuroendocrine carcinomas rising in this area such as small-cell neuroendocrine carcinoma (SCNEC) and large-cell sinonasal neuroendocrine carcinoma (SNEC). Salivary-type malignancies, mesenchymal tumours and mucosal melanoma of the sinonasal tract have been excluded, since dedicated guidelines already exist.